| Project/Area Number |
25460677
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
Osada Makoto 山梨大学, 医学部附属病院, 臨床検査技師 (20569628)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
INOUE Osamu 山梨大学, 総合研究部, 准教授 (00432154)
OZAKI Yukio 山梨大学, 総合研究部, 教授 (30134539)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | soluble CLEC-2 / ポドプラニン / 血小板活性化マーカー / 慢性関節リウマチ / 抗血小板薬 / 抗血小板剤 |
|---|
| Outline of Final Research Achievements |
In the present study, we investigated whether plasma sCLEC-2 can be used for a drug monitoring of anti-platelet drug and whether it can be used for a predictive factor of distant metastasis in patients with squamous cell carcinoma, seminoma, and brain tumor. In addition, we investigated whether plasma sCLEC-2 is elevated in patients with rheumatoid arthritis. We also aimed to establish a sCLEC-2 measuring method using general-purpose equipment. Measurement of sCLEC-2 is simple compared with the conventional method. Moreover, we found that plasma sCLEC-2 is elevated in patients with rheumatoid arthritis and diabetes mellitus. Therefore, it is suggested that plasma sCLEC-2 can be used for a marker of in vivo platelet activation. Unfortunately, we were not able to establish a sCLEC-2 measuring method using general-purpose equipment. But sCLEC-2 is expected as a novel laboratory test for detecting in vivo platelet activation.
|
